ArticleJournal, genetic engineering & biotechnology2025
Loss-of-function variant of SLC30A8 rs13266634 (C > T) protects against type 2 diabetes by stabilizing ZnT8: Insights from epidemiological and computational analyses.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The loss-of-function variant rs13266634 (C > T) in SLC30A8 has been linked to type-2-diabetes (T2D) susceptibility with conflicting findings. We investigated its role among T2D patients of Bangladesh. The rs13266634 (C > T) variant results in an arginine-to-tryptophan (p.R325W) substitution of SLC30A8-encoded zinc transporter protein, ZnT8. As zinc is crucial for insulin-crystallization for storage, we analyzed its wild-type (WZnT8) and variant (MZnT8) protein conformations via molecular-dynamics (MD) simulations. For the epidemiological analysis, a case-control study was conducted with 90 T2D patients from a diabetic-patient-cohort and 90 gender-matched healthy-controls. Genomic DNA was isolated from blood samples and genotyped by Sanger sequencing. MD simulations, spanning over 100 ns, were executed using GROMACS v2024.4. The homozygous wild CC-genotype was significantly more frequent in T2D patients (66.7 %) than in control (50.0 %) and was increasing T2D risk, with adjusted odds-ratio (OR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.